ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Clin Microbiol Infect · 2026-02-10

Secondary analysis of the CAMERA2 trial (150 combination-therapy patients with MRSA bacteraemia): in vitro synergy or additivity with a β-lactam did not change the primary 90-day mortality composite (32% vs 34%), though 14-day mortality was lower (2.9% vs 12.8%).

Secondary analysisn = 150
Soo et al. Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.